"Nothing strengthens authority so much as silence.”? Leonardo da Vinci
Today, we are circling back and revisiting the investment case on Omeros (OMER) after this 'Tier 3' concern posted quarterly results on Tuesday. Like so many biotech/biopharma names, sales from its approved compound Omidria were impacted by the impacts of Covid19. Fortunately, these revenues look like they will be delayed not lost as these types of elective surgeries are necessary and will eventually happen. We also update investors on the status of two items that will determine the direction of